
This study aimed to define RVD in patients undergoing M‐TEER for primary MR (PMR) and to evaluate its impact on procedural MR reduction, symptomatic development and 2‐year all‐cause mortality. 648 PMR patients were included in the study. DC and VC were comparable regarding procedural success and outcomes at follow‐up. M‐TEER is an effective treatment option for PMR patients. However, the presence of RVD is associated with less MR reduction, less symptomatic improvement and increased 2‐year mortality. Accordingly, RVD might be included in preprocedural prognostic considerations.
Like
Save
Share